+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives



Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives



Lancet 384(9942): 545-555



Several important advances have been made in our understanding of the pathways that lead to cell dysfunction and death in Parkinson's disease and Huntington's disease. These advances have been informed by both direct analysis of the post-mortem brain and by study of the biological consequences of the genetic causes of these diseases. Some of the pathways that have been implicated so far include mitochondrial dysfunction, oxidative stress, kinase pathways, calcium dysregulation, inflammation, protein handling, and prion-like processes. Intriguingly, these pathways seem to be important in the pathogenesis of both diseases and have led to the identification of molecular targets for candidate interventions designed to slow or reverse their course. We review some recent advances that underlie putative therapies for neuroprotection in Parkinson's disease and Huntington's disease, and potential targets that might be exploited in the future. Although we will need to overcome important hurdles, especially in terms of clinical trial design, we propose several target pathways that merit further study. In Parkinson's disease, these targets include agents that might improve mitochondrial function or increase degradation of defective mitochondria, kinase inhibitors, calcium channel blockers, and approaches that interfere with the misfolding, templating, and transmission of α-synuclein. In Huntington's disease, strategies might also be directed at mitochondrial bioenergetics and turnover, the prevention of protein dysregulation, disruption of the interaction between huntingtin and p53 or huntingtin-interacting protein 1 to reduce apoptosis, and interference with expression of mutant huntingtin at both the nucleic acid and protein levels.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055815528

Download citation: RISBibTeXText

PMID: 24954676

DOI: 10.1016/s0140-6736(14)61010-2


Related references

The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. Neurorx 1(1): 128-138, 2005

GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. Expert Opinion on Therapeutic Targets 5(2): 219-239, 2005

Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metabolism 4(5): 349-362, 2006

The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97(3): 505-519, 2000

Therapeutic prospects for the prevention of neurodegeneration in Huntington's disease and the polyglutamine repeat disorders. Mini Reviews in Medicinal Chemistry 7(1): 99-106, 2007

B11Targeting the Nrf2 pathway in Huntington's disease: fumaric acid esters as a new therapeutic option in neurodegeneration?. Journal of Neurology, Neurosurgery & Psychiatry 81(Suppl 1): A14.1-A14, 2010

Huntington's disease: pathomechanism and therapeutic perspectives. Journal of Neural Transmission 111(10-11): 1485-1494, 2004

Huntington's disease: novel therapeutic perspectives hanging in the balance. Expert Opinion on Therapeutic Targets 22(5): 385-399, 2018

Cognitive slowing in Parkinson's disease: a behavioral evaluation independent of motor slowing. Journal of Neuroscience 22(12): 5198-5203, 2002

Cognitive Slowing in Parkinson's Disease: A Behavioral Evaluation Independent of Motor Slowing. The Journal of Neuroscience 22(12): 5198-5203, 2002

Accelerating the natural history of neurodegeneration in Huntington disease YAC transgenic mice Facilitation of in vivo screening of potential therapeutic agents. American Journal of Human Genetics 67(4 Suppl. 2): 427, 2000

Modeling Huntington disease in yeast: perspectives and future directions. Prion 5(4): 269-276, 2013

Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals. Archiv für Psychiatrie und Nervenkrankheiten 230(1): 5-15, 1981

Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histology and Histopathology 23(2): 237-250, 2007

Protection against dopaminergic neurodegeneration in Parkinson's disease-model animals by a modulator of the oxidized form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7. Journal of Pharmacological Sciences 117(3): 189-203, 2012